Q3 sales rose 7% and adjusted EPS was $1.42, with growth accelerating. Plans call for a tax-free nutrition separation by end-2027; near-term outlook reflects EP and diabetes headwinds, while 2027 growth acceleration is expected.Based on Abbott Laboratories [ABT] Q3 2026 Audio Transcript — Oct. 21 2…